1,937
Views
8
CrossRef citations to date
0
Altmetric
Original Research Article

Circulating LL37 targets plasma extracellular vesicles to immune cells and intensifies Behçet’s disease severity

, , , , , , , , , , & show all
Article: 1284449 | Received 04 Mar 2016, Accepted 03 Dec 2016, Published online: 28 Feb 2017

References

  • Comarmond C, Wechsler B, Bodaghi B, et al. Biotherapies in Behcet’s disease. Autoimmun Rev. 2014;13:1–13.
  • Hatemi G, Merkel PA, Hamuryudan V, et al. Outcome measures used in clinical trials for Behcet syndrome: a systematic review. J Rheumatol. 2014;41:599–612.
  • Direskeneli H. Autoimmunity vs autoinflammation in Behcet’s disease: do we oversimplify a complex disorder? Rheumatology. 2006;45:1461–1465.
  • Emmi G, Silvestri E, Squatrito D, et al. Behcet’s syndrome pathophysiology and potential therapeutic targets. Intern Emerg Med. 2014;9:257–265.
  • Yazici Y, Yurdakul S, Yazici H. Behcet’s syndrome. Curr Rheumatol Rep. 2010;12:429–435.
  • Hamzaoui K, Hamzaoui A, Guemira F, et al. Cytokine profile in Behcet’s disease patients. Relationship with disease activity. Scand J Rheumatol. 2002;31:205–210.
  • Hatemi G, Yazici Y, Yazici H. Behcet’s syndrome. Rheum Dis Clin North Am. 2013;39:245–261.
  • Melikoglu M, Uysal S, Krueger JG, et al. Characterization of the divergent wound-healing responses occurring in the pathergy reaction and normal healthy volunteers. J Immunol. 2006;177:6415–6421.
  • Raziuddin S, Al-Dalaan A, Bahabri S, et al. Divergent cytokine production profile in Behcet’s disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol. 1998;25:329–333.
  • Raizman MB, Foster CS. Plasma exchange in the therapy of Behcet’s disease. Graefes Arch Clin Exp Ophthalmol. 1989;227:360–363.
  • Distler JH, Huber LC, Gay S, et al. Microparticles as mediators of cellular cross-talk in inflammatory disease. Autoimmunity. 2006;39:683–690.
  • Théry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009;9:581–593.
  • Distler JH, Jungel A, Huber LC, et al. The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc Natl Acad Sci U S A. 2005;102:2892–2897.
  • Barry OP, Praticò D, Savani RC, et al. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest. 1998;102:136–144.
  • Duval A, Helley D, Capron L, et al. Endothelial dysfunction in systemic lupus patients with low disease activity: evaluation by quantification and characterization of circulating endothelial microparticles, role of anti-endothelial cell antibodies. Rheumatology (Oxford). 2010;49:1049–1055.
  • Ullal AJ, Pisetsky DS. The release of microparticles by Jurkat leukemia T cells treated with staurosporine and related kinase inhibitors to induce apoptosis. Apoptosis. 2010;15:586–596.
  • VanWijk MJ, VanBavel E, Sturk A, et al. Microparticles in cardiovascular diseases. Cardiovasc Res. 2003;59:277–287.
  • Gauley J, Pisetsky DS. The release of microparticles by RAW 264.7 macrophage cells stimulated with TLR ligands. J Leukoc Biol. 2010;87:1115–1123.
  • Beyer C, Pisetsky DS. The role of microparticles in the pathogenesis of rheumatic diseases. Nat Rev Rheumatol. 2010;6:21–29.
  • Berckmans RJ, Nieuwland R, Kraan MC, et al. Synovial microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes. Arthritis Res Ther. 2005;7:R536–R544.
  • Berckmans RJ, Nieuwland R, Tak PP, et al. Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthritis Rheum. 2002;46:2857–2866.
  • Brogan PA, Shah V, Brachet C, et al. Endothelial and platelet microparticles in vasculitis of the young. Arthritis Rheum. 2004;50:927–936.
  • Brogan PA, Dillon MJ. Endothelial microparticles and the diagnosis of the vasculitides. Intern Med. 2004;43:1115–1119.
  • Combes V, Simon AC, Grau GE, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest. 1999;104:93–102.
  • Guiducci S, Distler JH, Jungel A, et al. The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. Arthritis Rheum. 2008;58:2845–2853.
  • Knijff-Dutmer EA, Koerts J, Nieuwland R, et al. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum. 2002;46:1498–1503.
  • Larkin M. Raised endothelial microparticles an early marker for multiple sclerosis? Lancet. 2001;357:1679.
  • Minagar A, Jy W, Jimenez JJ, et al. Elevated plasma endothelial microparticles in multiple sclerosis. Neurology. 2001;56:1319–1324.
  • Sellam J, Proulle V, Jungel A, et al. Increased levels of circulating microparticles in primary Sjogren’s syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. Arthritis Res Ther. 2009;11:R156.
  • van Eijk IC, Tushuizen ME, Sturk A, et al. Circulating microparticles remain associated with complement activation despite intensive anti-inflammatory therapy in early rheumatoid arthritis. Ann Rheum Dis. 2010;69:1378–1382.
  • Dye JR, Ullal AJ, Pisetsky DS. The role of microparticles in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Scand J Immunol. 2013;78:140–148.
  • Criteria for diagnosis of Behcet’s disease. International study group for Behcet’s disease. Lancet. 1990;335:1078–1080.
  • Thery C, Amigorena S, Raposo G, et al. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006;Chapter 3:Unit 3 22.
  • Gursel I, Gursel M, Yamada H, et al. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol. 2003;171:1393–1400.
  • Kahlenberg JM, Kaplan MJ. Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. J Immunol. 2013;191:4895–4901.
  • Lynch SF, Ludlam CA. Plasma microparticles and vascular disorders. Br J Haematol. 2007;137:36–48.
  • Hurtado P, Peh CA. LL-37 promotes rapid sensing of CpG oligodeoxynucleotides by B lymphocytes and plasmacytoid dendritic cells. J Immunol. 2010;184:1425–1435.
  • Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol. 2009;19:43–51.
  • Hunter MP, Ismail N, Zhang X, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One. 2008;3:e3694.
  • Reich CF 3rd, Pisetsky DS. The content of DNA and RNA in microparticles released by Jurkat and HL-60 cells undergoing in vitro apoptosis. Exp Cell Res. 2009;315:760–768.
  • Hugel B, Martínez MC, Kunzelmann C, et al. Membrane microparticles: two sides of the coin. Physiology (Bethesda). 2005;20:22–27.
  • Yáñez-Mó M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066.
  • Wang YQ, Johansson J, Agerberth B, et al. The antimicrobial peptide LL-37 binds to the human plasma protein apolipoprotein A-I. Rapid Commun Mass Spectrom. 2004;18:588–589.
  • Wang Y, Agerberth B, Löthgren A, et al. Apolipoprotein A-I binds and inhibits the human antibacterial/cytotoxic peptide LL-37. J Biol Chem. 1998;273:33115–33118.
  • Dean SN, Bishop BM, van Hoek ML. Susceptibility of Pseudomonas aeruginosa biofilm to alpha-helical peptides: D-enantiomer of LL-37. Front Microbiol. 2011;2:128.
  • Wong JH, Ng TB, Legowska A, et al. Antifungal action of human cathelicidin fragment (LL13-37) on Candida albicans. Peptides. 2011;32:1996–2002.
  • Barlow PG, Svoboda P, Mackellar A, et al. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One. 2011;6:e25333.
  • Mumcu G, Cimilli H, Karacayli U, et al. Salivary levels of antimicrobial peptides Hnp 1-3, Ll-37 and S100 in Behcet’s disease. Arch Oral Biol. 2012;57:642–646.
  • Vandamme D, Landuyt B, Luyten W, et al. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol. 2012;280:22–35.
  • Yu J, Mookherjee N, Wee K, et al. Host defense peptide LL-37, in synergy with inflammatory mediator IL-1beta, augments immune responses by multiple pathways. J Immunol. 2007;179:7684–7691.
  • Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449:564–569.